Animal Health Active Pharmaceutical Ingredients Market Trends and Demand 2017-2025

Western regulatory agencies are taking stringent actions on the APIs produced
in these region. The companies engaged in production are facing challenges
while bridging the gap between cost and the quality of APIs. Strict validations
and guidelines set by regulatory agencies are expected to hamper the growth of
API market in APAC region.
Europe to Remain the Second Largest Market for Animal Health APIs
Europe is expected to remain the second largest market for animal health active
pharmaceutical ingredients. Most of the leading healthcare companies operating
through Europe continuously require bulk amount of animal grade APIs. In
addition, consumption of animal grade API has increased substantially over the
past few years. Spain is one of the largest consumer of animal-grade
antimicrobial APIs in Europe.
APIs can facilitate productivity enhancement, which is of significant value to
the animal healthcare industry. Such factors are expected to augment the growth
of animal health API market in EU. Stringent approval process implemented by
the European Medicinal Agency (EMA) only permits registered APIs for their
use in production of pharmaceuticals. This is likely to result shortage of
intermediates and materials. The stringent guidelines as well as fragmented
market are likely to curb the market growth of animal grade API in Europe.
Request and Download Sample Report@
https://www.persistencemarketresearch.com/samples/16972
Antiparasitics to Remain in Large Demand in the Market
• Anti-parasitics expected to be the largely adopted active pharmaceutical
ingredient in the market
• Frequent bacterial infection to pets demands Anti-infective, which in turn
projected to account for the largest revenue by 2025-end
• Revenues from the sale of anesthetics and NSIDs will remain same as
compared to the collective revenues of anti-parasitics and anti-infectives
Key market players profiled in PMR’s report include Glenmark Pharmaceutical
Limited., Zoetis, Inc., Eli Lilly & Co., Sanofi Winthrop Industrie (CEPiA),
Indukern, S.A., Ofichem BV, P&R S.p.A (Olon S.p.A), Lonza Group AG,
Huvepharma AD, Ourofino Saude Animal, Blanver Farmoquimica E
Farmaceutica S.A., Zhejiang Hisun Pharmaceutical Co., Ltd, Changzhou
Yabang-Qh Pharmachem Co., Ltd., Shanghai Pharmtech Co., Ltd., Ningxia